FARS2 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL116095	1.00	5/20
SCHEMBL116106	1.00	5/20
SCHEMBL117295	1.00	5/20
SCHEMBL117488	1.00	5/20
SCHEMBL117490	1.00	5/20
SCHEMBL117501	1.00	5/20
SCHEMBL117504	1.00	5/20
SCHEMBL118476	1.00	5/20
SCHEMBL13104433	0.75	5/20
SCHEMBL13104371	0.74	5/20
SCHEMBL13104427	0.74	5/20
SCHEMBL14592639	0.66	5/20
SCHEMBL13104431	0.57	5/20
SCHEMBL13843264	0.57	5/20
SCHEMBL14565750	0.57	5/20
SCHEMBL5384839	0.56	5/20
SCHEMBL14592567	0.56	5/20
SCHEMBL29941604	0.56	5/20
SCHEMBL13104419	0.54	5/20
SCHEMBL13199995	0.54	5/20

Clinical trials — most relevant to FARS2 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
A Study of the Efficacy and Safety of MT1621 in Thymidine Kinase 2 (TK2) Deficiency (Treatment naïve)	PHASE3	WITHDRAWN
Nicotinamide Riboside on Mitochondrial Function in Li-Fraumeni Syndrome	PHASE1/PHASE2	COMPLETED
Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder	PHASE2	WITHDRAWN
EPI-743 for Metabolism or Mitochondrial Disorders	PHASE1/PHASE2	COMPLETED
Tissue Sample Study for Mitochondrial Disorders	nan	ENROLLING_BY_INVITATION
Natural History Study of Leukoencephalopathy With Brainstem and Spinal Cord Involvement and Lactate Elevation (LBSL)	nan	RECRUITING
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide	nan	RECRUITING
Exercise-mediated Rescue of Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease	nan	COMPLETED
Nicotinamide Riboside and Mitochondrial Biogenesis	nan	COMPLETED
Mitochondrial Dysfunction in Phelan-McDermid Syndrome	nan	COMPLETED
Mitochondrial Dysfunctions Driving Insulin Resistance	nan	COMPLETED
Mitochondrial Disease-associated ImmunoDeficiencies	nan	RECRUITING
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Effect of Branched Chain Amino Acids on Muscle	nan	COMPLETED
Mitoferrin-1 Expression in Erythropoietic Protoporphyria (Porphyria Rare Disease Clinical Research Consortium (RDCRC))	nan	COMPLETED
Quantifying Disease Progression in LBSL	nan	UNKNOWN
Natural History in Primary Mitochondrial Myopathies	nan	RECRUITING
The Genetics of Diabetes in Southern California Chinese Americans	nan	WITHDRAWN
Pathogenic Insights and Search for Biomarkers in RFC1-ataxia/CANVAS	nan	RECRUITING
Calf Muscle Strength in Mitochondrial Diseases	nan	COMPLETED
North American Mitochondrial Disease Consortium Patient Registry and Biorepository (NAMDC)	nan	RECRUITING
Fatty Acid Oxidation Defects and Insulin Sensitivity	nan	COMPLETED
MITOMICS : a Multi-OMICS Approach for the Diagnosis of Mitochondrial Diseases	nan	RECRUITING
Mitoquines in COPD	nan	UNKNOWN
Genomic Profiling of Mitochondrial Disease - Imaging Analysis for Precise Mitochondrial Medicine	nan	COMPLETED
Skeletal Muscle Regeneration in Survivors of Critical Illness: How to Prevent Satellite Cell Failure?	nan	RECRUITING
Choroid Plexus Dysfunction in Neurological Diseases	nan	RECRUITING
Gastrointestinal Dysfunction in Children Affected With Mitochondrial Disorders	nan	COMPLETED
Effect of Subtle Energy Transmission and Tao Calligraphy Mindfulness Practice on Mitochondrial DNA in Peripheral Blood Leukocytes	nan	NOT_YET_RECRUITING

Related proteins — ESM-2 sequence neighbours (a FARS2 binder may also engage these)

Protein	Name	Similarity
Q99M01	—	1.000	Q99M01 →
Q6AYQ3	—	1.000	Q6AYQ3 →
Q96I59	—	0.986	Q96I59 →
A2RTX5	—	0.983	A2RTX5 →
Q8BGV0	—	0.983	Q8BGV0 →
Q8BLY2	—	0.982	Q8BLY2 →
O16129	—	0.981	O16129 →
TARS2	Threonine--tRNA ligase, mitochondrial	0.981	landscape →
A6QNM8	—	0.980	A6QNM8 →
Q0V9S0	—	0.980	Q0V9S0 →
Q9VUJ0	—	0.980	Q9VUJ0 →
GARS1	Glycine--tRNA ligase	0.979	landscape →
O74952	—	0.979	O74952 →
Q5RBL1	—	0.977	Q5RBL1 →
Q8RWT8	—	0.977	Q8RWT8 →
Q99KK9	—	0.977	Q99KK9 →
Q9JJL8	—	0.976	Q9JJL8 →
Q5JTZ9	—	0.976	Q5JTZ9 →
Q15031	—	0.976	Q15031 →
A2RV18	—	0.976	A2RV18 →
Q5XHY5	—	0.976	Q5XHY5 →
Q3ZBV8	—	0.976	Q3ZBV8 →
NAT10	RNA cytidine acetyltransferase	0.976	landscape →
SARS1	Serine--tRNA ligase, cytoplasmic	0.976	landscape →
Q99MN1	—	0.976	Q99MN1 →
Q5XIM7	—	0.976	Q5XIM7 →
Q6PI48	—	0.976	Q6PI48 →
P08425	—	0.976	P08425 →
Q9D0R2	—	0.975	Q9D0R2 →
Q2T9L8	—	0.975	Q2T9L8 →